NRG Oncology RTOG 0617长期结果:不可切除III期NSCLC标准剂量与高剂量放化疗联合或不联合西妥昔单抗
RTOG 0617研究采用2×2析因设计,比较标准剂量(60 Gy)与高剂量(74 Gy)放疗联合化疗,并评估西妥昔单抗在III期非小细胞肺癌中的疗效。结论认为60 Gy联合化疗仍为标准治疗,西妥昔单抗无生存获益且增加毒性。
要点
- 高剂量组治疗相关≥3级吞咽困难和食管炎发生率显著更高。
- 西妥昔单抗未带来生存获益,反而增加毒性。
核心结论
- 60 Gy放疗联合化疗应继续作为III期非小细胞肺癌的标准治疗。
- 西妥昔单抗对总生存无影响,且增加毒性。
研究设计与样本
- 研究采用2×2析因设计,放疗剂量(标准剂量60 Gy vs 高剂量74 Gy)和西妥昔单抗为两个因素。
- 主要终点为总生存期(OS)。
主要发现
- 两组≥3级肺毒性发生率无差异(20.6% vs 19.3%)。
- 多变量分析中与OS改善相关的因素包括标准放疗剂量、肿瘤位置、机构入组量、食管炎/吞咽困难、计划靶体积和心脏V5。
关键数值与推荐
- 标准剂量组和 高剂量组分别有3例和9例5级不良事件。
- 标准剂量组完成治疗后1个月内进展率为4.6%,校正后2年OS率和PFS率分别为59.6%和30.7%。
临床怎么用
- 对于不可切除III期非小细胞肺癌,推荐使用60 Gy放疗联合化疗,不应常规联用西妥昔单抗。
- 需关注高剂量放疗带来的吞咽困难和食管炎风险。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non-small-cell lung cancer (NSCLC). METHODS: The study used a 2 × 2 factorial design with radiation dose as 1 factor and cetuximab as the other, with a primary end point of overall survival (OS). RESULTS: Median follow-up was 5.1 years. There were 3 grade 5 adverse events (AEs) in the SD arm and 9 in the HD arm. Treatment-related grade ≥3 dysphagia and esophagitis occurred in 3.2% and 5.0% of patients in the SD arm v 12.1% and 17.4% in the HD arm, respectively (P = .0005 and < .0001). There was no difference in pulmonary toxicity, with grade ≥3 AEs in 20.6% and 19.3%. Median OS was 28.7 v 20.3 months (P = .0072) in the SD and HD arms, respectively, 5-year OS and progression-free survival (PFS) rates were 32.1% and 23% and 18.3% and 13% (P = .055), respectively. Factors associated with improved OS on multivariable analysis were standard radiation dose, tumor location, institution accrual volume, esophagitis/dysphagia, planning target volume and heart V5. The use of cetuximab conferred no survival benefit at the expense of increased toxicity. The prior signal of benefit in patients with higher H scores was no longer apparent. The progression rate within 1 month of treatment completion in the SD arm was 4.6%. For comparison purposes, the resultant 2-year OS and PFS rates allowing for that dropout rate were 59.6% and 30.7%, respectively, in the SD arms. CONCLUSION: A 60-Gy radiation dose with concurrent chemotherapy should remain the standard of care, with the OS rate being among the highest reported in the literature for stage III NSCLC. Cetuximab had no effect on OS. The 2-year OS rates in the control arm are similar to the PACIFIC trial.
引用
- Bradley JD, Hu C, Komaki RR, et al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2019. PMID: 31841363. doi:10.1200/JCO.19.01162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。